JACC. Case reports · 2026
Transthyretin Amyloidosis Due to a Rare TTR Val142del Deletion With Relatively Early Clinical Manifestations.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Espinoza Romero Cristhian, De Paula Morales Kevin, Espirito Santo Christiane, Dos Santos Ferreira Guilherme, Silva Martins Alan, Kerges Bueno Bruno Vaz, Fernandes Fabio
Аннотация
BACKGROUND: Hereditary transthyretin amyloidosis shows marked phenotypic heterogeneity. In-frame deletions at codon 142 are exceedingly rare, and their cardiac expression remains poorly characterized.
CASE SUMMARY: A 62-year-old man presented with progressive neuropathy, autonomic dysfunction, weight loss, and recurrent syncope. Multimodality imaging demonstrated concentric hypertrophy with preserved ejection fraction, apical sparing on strain, diffuse late gadolinium enhancement with increased extracellular volume, and grade III uptake on 99mTc-pyrophosphate scintigraphy. Monoclonal gammopathy was excluded. Genetic testing identified a heterozygous the transthyretin p.Val142del deletion. Autonomic testing confirmed orthostatic hypotension with impaired chronotropic response. Heart failure therapy and tafamidis led to symptomatic improvement. Cascade screening identified 2 asymptomatic carriers.
DISCUSSION: Unlike the common Val142Ile substitution, this deletion appears associated with earlier penetrance and multisystem involvement.
TAKE-HOME MESSAGES: Rare transthyretin deletions may cause aggressive hereditary transthyretin amyloidosis. Early recognition and family screening are essential.
CASE SUMMARY: A 62-year-old man presented with progressive neuropathy, autonomic dysfunction, weight loss, and recurrent syncope. Multimodality imaging demonstrated concentric hypertrophy with preserved ejection fraction, apical sparing on strain, diffuse late gadolinium enhancement with increased extracellular volume, and grade III uptake on 99mTc-pyrophosphate scintigraphy. Monoclonal gammopathy was excluded. Genetic testing identified a heterozygous the transthyretin p.Val142del deletion. Autonomic testing confirmed orthostatic hypotension with impaired chronotropic response. Heart failure therapy and tafamidis led to symptomatic improvement. Cascade screening identified 2 asymptomatic carriers.
DISCUSSION: Unlike the common Val142Ile substitution, this deletion appears associated with earlier penetrance and multisystem involvement.
TAKE-HOME MESSAGES: Rare transthyretin deletions may cause aggressive hereditary transthyretin amyloidosis. Early recognition and family screening are essential.